DE69521323T2 - Quinoxalindion-nmda rezeptorantagonisten - Google Patents

Quinoxalindion-nmda rezeptorantagonisten

Info

Publication number
DE69521323T2
DE69521323T2 DE69521323T DE69521323T DE69521323T2 DE 69521323 T2 DE69521323 T2 DE 69521323T2 DE 69521323 T DE69521323 T DE 69521323T DE 69521323 T DE69521323 T DE 69521323T DE 69521323 T2 DE69521323 T2 DE 69521323T2
Authority
DE
Germany
Prior art keywords
pct
alkyl
group
date mar
ch2ch3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69521323T
Other languages
English (en)
Other versions
DE69521323D1 (de
Inventor
Eric Mowbray
Alan Stobie
John Bull
Lee Carr
Johnathan Fray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Ltd
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Pfizer Research and Development Co NV SA filed Critical Pfizer Ltd
Publication of DE69521323D1 publication Critical patent/DE69521323D1/de
Application granted granted Critical
Publication of DE69521323T2 publication Critical patent/DE69521323T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69521323T 1994-09-13 1995-09-01 Quinoxalindion-nmda rezeptorantagonisten Expired - Fee Related DE69521323T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents
PCT/EP1995/003483 WO1996008485A1 (en) 1994-09-13 1995-09-01 Quinoxalinedione nmda receptor antagonists

Publications (2)

Publication Number Publication Date
DE69521323D1 DE69521323D1 (de) 2001-07-19
DE69521323T2 true DE69521323T2 (de) 2001-09-20

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521323T Expired - Fee Related DE69521323T2 (de) 1994-09-13 1995-09-01 Quinoxalindion-nmda rezeptorantagonisten

Country Status (14)

Country Link
US (1) US5783572A (de)
EP (1) EP0781279B1 (de)
JP (1) JP2898097B2 (de)
AT (1) ATE202099T1 (de)
CA (1) CA2199845C (de)
DE (1) DE69521323T2 (de)
DK (1) DK0781279T3 (de)
ES (1) ES2158126T3 (de)
FI (1) FI113471B (de)
GB (1) GB9418443D0 (de)
GR (1) GR3036270T3 (de)
MX (1) MX9701894A (de)
PT (1) PT781279E (de)
WO (1) WO1996008485A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
AU5367598A (en) * 1996-11-25 1998-06-22 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EP2089383B1 (de) 2006-11-09 2015-09-16 Probiodrug AG 3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2009014216A (es) * 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
BR112013014484A2 (pt) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung

Also Published As

Publication number Publication date
JP2898097B2 (ja) 1999-05-31
PT781279E (pt) 2001-09-28
GR3036270T3 (en) 2001-10-31
JPH09511523A (ja) 1997-11-18
CA2199845C (en) 2000-08-01
FI971026A0 (fi) 1997-03-12
FI971026A (fi) 1997-03-12
WO1996008485A1 (en) 1996-03-21
FI113471B (fi) 2004-04-30
ATE202099T1 (de) 2001-06-15
CA2199845A1 (en) 1996-03-21
MX9701894A (es) 1997-06-28
DE69521323D1 (de) 2001-07-19
EP0781279B1 (de) 2001-06-13
GB9418443D0 (en) 1994-11-02
DK0781279T3 (da) 2001-09-03
US5783572A (en) 1998-07-21
EP0781279A1 (de) 1997-07-02
ES2158126T3 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
DE69521323D1 (de) Quinoxalindion-nmda rezeptorantagonisten
FI962753A (fi) Menetelmä lääkeaineena käytt¦kelpoisen piperidyyli- tai pyrrolidiinijohdannaisen tai sen farmaseuttisen suolan valmistamiseksi
ZA928682B (en) Acyclic ethylenediamine derivatives
DE69225500T2 (de) Chinazolinone als mittel gegen angina
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
NZ508910A (en) Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists
DE69528485D1 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
ATE297381T1 (de) Ether-muskarinantagonisten
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
NZ333513A (en) 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
ATE214056T1 (de) Benzodiazepinderivate
DK0553278T3 (da) 2-Phenyl- og 2-thienyl-(2)-piperidinderivater med neurobeskyttende egenskaber
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee